Fundrise Innovation Fund (VCX) Review: A 1,500% NAV Premium You Shouldn't Buy
TL;DR: Fundrise Innovation Fund converted from a quarterly tender-offer fund into an NYSE-listed closed-end fund (ticker VCX) on March 19, 2026. Shares traded as high as roughly $315 against a net...
TL;DR: Fundrise Innovation Fund converted from a quarterly tender-offer fund into an NYSE-listed closed-end fund (ticker VCX) on March 19, 2026. Shares traded as high as roughly $315 against a net asset value of $18.97, a premium north of 1,500%, while the fund simultaneously raised its management fee from 1.85% to 2.50% and locked up legacy holders for six months. You are being asked to pay a scarcity tax for indirect exposure to Anthropic, OpenAI, Databricks, Anduril, and SpaceX. That tax has crushed buyers of a nearly identical vehicle before.
According to Morningstar, Fundrise Innovation is not worth getting up for at these prices, and Morningstar's Jack Shannon has said so in print. That is a strong statement from an analyst shop that does not usually editorialize about listed funds. I read the underlying SEC filings before writing this, and I think Shannon undersold it. The gap between what VCX actually owns and what people are paying for it is one of the widest I have seen in a listed product in years.
Let's start with what the fund is, because the structure matters more than the logo on the ticker.
What VCX Actually Is
Fundrise Innovation Fund launched as an evergreen, tender-offer-based venture fund. Retail investors bought in continuously through the Fundrise platform, and the fund offered to buy back up to 5% of net assets each quarter if holders wanted out. That structure is common in the interval-fund and non-traded BDC world. It trades liquidity for access: you cannot sell whenever you want, but you also are not subject to the moment-to-moment mood swings of a public market, because there is no public market. The fund's own board noted in its February 2026 proxy filing that actual Q4 2025 redemption requests ran about 1.5% of shares, well under the 5% cap, meaning most legacy holders were not even trying to leave. That changed in March 2026. Fundrise took the fund public on the NYSE under the ticker VCX, converting it into a closed-end fund with continuously tradable shares. Closed-end funds have a fixed share count (unlike open-end mutual funds) and trade at whatever price buyers and sellers agree on, which can and often does diverge from the underlying net asset value, or NAV, the per-share value of the fund's actual holdings.
The conversion came with two changes that mattered a lot more to existing shareholders than to new buyers. First, the management fee rose from 1.85% to 2.50% of average daily net assets, a 35% increase, approved by proxy vote in February 2026. Second, the roughly 100,000 legacy investors who had funded the portfolio through the original evergreen structure were subject to a six-month lockup on their shares following the listing. New buyers on the NYSE faced no such restriction. They could buy and sell VCX the day it started trading. The people who had actually built the portfolio through years of capital contributions could not sell into the frenzy that followed.
The Premium Is the Whole Story
Here is the number that should stop you cold. As of the fund's most recent N-CSR/A filing, NAV per share sat at $18.97, with net assets around $679 million and about 28.35 million shares outstanding. Days after the March 19, 2026 listing, shares traded as high as approximately $315, according to reporting from the Economic Times, which cited Bloomberg data showing the stock up more than 1,200% above its asset value at one point and trading halted twice for volatility. That is not a typo, and it is not a rounding issue. $315 divided by $18.97 works out to roughly 16.6x NAV. Some intraday prints reportedly pushed the premium above 1,500%. You are paying sixteen to seventeen dollars for every one dollar of actual fund assets. I want you to sit with that ratio before we even get to what the fund holds.
Why would anyone pay that? Scarcity. The float, the number of shares actually available to trade, was tiny relative to demand because most of the shares outstanding belonged to legacy holders stuck in the six-month lockup. A small number of shares chasing a large amount of retail excitement about AI exposure is a textbook setup for a price that has nothing to do with fundamentals. This is not a venture-return thesis. It's a supply-and-demand mismatch on a thin float, and thin floats are unstable by nature.
What's Actually in the Portfolio
Strip away the trading price and look at what VCX owns, because the holdings themselves are genuinely interesting, even if the price is not.
| Holding | Approx. % of Net Assets | Sector |
|---|---|---|
| Anthropic | 16.5% | AI / large language models |
| Databricks | 14.1% | Data & AI infrastructure |
| OpenAI | 12.4% | AI / large language models |
| Anduril (Palmer Luckey) | 5.5% | Defense technology |
| Ramp | 4.1% | Corporate fintech |
| Space Exploration Technologies Corp. (SpaceX) | 4.0% | Aerospace |
| Top 10 holdings combined | 66.9% | Concentrated venture stakes |
That is a real portfolio of real companies, per the fund's schedule of investments in its SEC N-CSR/A filing. Anthropic, OpenAI, and Databricks alone account for about 43% of net assets. Add Anduril and SpaceX and you are looking at a fund that is essentially a concentrated bet, sized more like a hedge fund position than a diversified holding, on five private AI and defense-tech names. Other names in the filing include Epic Games, Flock Group, dbt Labs, and Erebor Bank, but those are rounding errors next to the top five. The fund reported a 12-month NAV return of +68.39% through the period covered by its June 2026 N-CSR/A filing. That is a genuinely strong return for a venture-style vehicle, and it reflects real markups in the underlying companies, not premium mania. NAV growth and market-price mania are two completely different phenomena, and VCX investors need to stop conflating them.
How You'd Actually Buy This (And Why the Mechanics Punish You)
If you want exposure to Anthropic or OpenAI, you cannot buy their stock directly. They are private companies. Retail platforms like Robinhood Markets do not list them because there is no public listing to offer. VCX is one of a small number of vehicles that gives ordinary investors indirect access to those stakes through a fund wrapper. The mechanism works like this: Fundrise, led by co-founder and CEO Ben Miller, raised capital from tens of thousands of investors over several years and used it to buy minority stakes in private companies, mostly through secondary transactions or direct rounds where Fundrise could negotiate access. Those stakes sit on the fund's books at values determined by Level 3 fair-value marks, meaning there is no active market price and the fund's valuation committee has to estimate value using comparable transactions, funding rounds, and internal models. Level 3 marks are inherently approximate. They can lag reality in either direction, and they get revised when a company raises a new round at a different valuation or when an IPO finally provides a real price. Once VCX moved to the NYSE, the fund itself did not change. The same Level 3-valued stakes sit inside it. What changed is that now there are two prices: the NAV, updated periodically by the fund based on those approximate marks, and the market price, set minute-to-minute by whoever is buying and selling on the exchange. When those two prices detach by 16x, you are not buying AI exposure at a fair price. You are buying a claim on AI exposure at a price set by people competing for a scarce number of shares, most of which are locked up and unavailable regardless of what any of them would sell for.
The Destiny Tech100 Precedent, and Why It Should Scare You
This is not the first time this movie has played. Destiny Tech100 is a closed-end fund that also holds stakes in SpaceX and OpenAI, among other private tech names. When it listed, it too traded at an enormous premium to NAV on the same logic: limited float, retail hunger for private AI and space exposure, no easy way to short an illiquid, thinly traded closed-end fund to correct the mispricing. That premium did not hold. It compressed hard once the initial listing euphoria faded and more shares became available to trade, and holders who bought near the peak sat on steep losses even though the underlying portfolio companies kept doing fine. VCX is now set up to repeat that pattern almost exactly, and the mechanics make it worse in one specific way: the six-month lockup on legacy holders. That lockup is due to expire roughly in mid-September 2026. When it does, a meaningful chunk of the roughly 28.35 million shares outstanding that have been sitting on the sidelines becomes sellable. If even a modest fraction of legacy holders, many of whom bought in at NAV years ago and have watched their paper gains balloon at a 16x premium, decide to take some profit, the float expands and the premium has nowhere to go but down. This is the single most predictable catalyst on the calendar for this fund, and it is sitting right there in the DEF 14A proxy filing that approved the conversion. I am not saying the fund is a fraud or that Anthropic and OpenAI stakes are worthless. I am saying the price you pay for the wrapper and the value of what's inside the wrapper are two different questions, and right now the gap between them is the widest I have seen on a listed U.S. fund outside of a handful of penny-stock pump situations.
What Could Go Right
I want to be fair to the other side of this, because a due-diligence review that only lists risk isn't doing its job either. If Anthropic, OpenAI, or SpaceX complete IPOs or major new funding rounds at valuations meaningfully above current marks, NAV itself could rise, and that would be a real, fundamental gain independent of the premium question. Databricks has been reportedly discussed as an IPO candidate, and a public listing would give VCX a hard, market-verified valuation on its second-largest holding instead of a Level 3 estimate. If NAV rises enough, some of today's absurd premium could get "earned back" by fundamentals over a multi-year horizon, even if the market price also falls in the near term. None of that changes the math on what you'd pay today. It just means the floor under this fund, over a long enough horizon, is probably not zero.
The Honest Risk Section
Here is what could blow up, stated plainly, because you deserve that more than you deserve reassurance. The premium could collapse fast once the lockup lifts in September 2026, the same way Destiny Tech100's premium compressed after its own listing rush. If you buy VCX today at anything close to a double-digit multiple of NAV, a reversion toward NAV, even a partial one, could cost you 50%, 70%, or more of your position, with no fundamental deterioration in the underlying companies required to cause it. The fee increase to 2.50% is a permanent drag that compounds every year you hold. On a $679 million net asset base, that fee alone runs north of $16 million annually, up from roughly $12.6 million under the old 1.85% rate. That money comes out of your return whether the fund is up or down. The Level 3 valuations on Anthropic, OpenAI, Databricks, and the rest are estimates, not market prices. They can be wrong in either direction, and a down round or a disappointing IPO at any of the top five holdings would hit both NAV and the market price at the same time, with the premium compression amplifying the pain. Liquidity for legacy holders was arguably better under the old tender-offer structure than it is now for anyone buying at today's market price, because at least under the old structure your redemption price was tied to actual NAV, not to whatever the crowd on the NYSE decided to pay that morning.
What I'd Actually Do
If you already hold VCX from the legacy Fundrise days and you're under lockup, there is nothing to do right now except plan for what happens when that lockup lifts around September 2026. Decide in advance whether you're selling into strength or holding for the long-term venture thesis, because deciding in the moment, with a stock that could be swinging 20% in a session, is a bad idea. If you're considering buying VCX fresh on the NYSE today, do not buy it as a way to get "cheap" access to Anthropic and OpenAI. You are not getting cheap access. You are paying a premium that dwarfs anything you'd pay for a normal venture fund's carry and fees combined. Pull up the fund's most recent NAV, published in its N-CSR filings on SEC.gov, compare it to the current trading price, and if the gap is anywhere near what it was in the weeks after listing, walk away. Set a price alert instead. If the premium ever compresses to something like 20% to 40% over NAV, that's a materially different, more defensible entry point than 1,500%. Read the DEF 14A proxy statement yourself before you buy anything. It has the fee schedule, the lockup terms, and the board's own disclosures about redemption history. Do not take my word or Morningstar's word for any of this when the primary document is sitting on SEC.gov for free.
Author Disclosure: Jeff Barnes, MBA has no personal position in any company, fund, or platform named in this article. Angel Investors Network has no current commercial relationship with any party mentioned. AIN provides marketing and education services, not investment advice. Past performance does not guarantee future results. All investments involve risk, including loss of principal.
Author Disclosure: Jeff Barnes, MBA has no personal position in any company, fund, or platform named in this article. Angel Investors Network has no current commercial relationship with any party mentioned. AIN provides marketing and education services, not investment advice. Past performance does not guarantee future results. All investments involve risk, including loss of principal.
Related on AIN
Author Disclosure: Jeff Barnes, MBA has no personal position in any company, fund, or platform named in this article. Angel Investors Network has no current commercial relationship with any party mentioned. AIN provides marketing and education services, not investment advice. Past performance does not guarantee future results. All investments involve risk, including loss of principal.
Author Disclosure: Jeff Barnes, MBA has no personal position in any company, fund, or platform named in this article. Angel Investors Network has no current commercial relationship with any party mentioned. AIN provides marketing and education services, not investment advice. Past performance does not guarantee future results. All investments involve risk, including loss of principal.
Topics
Looking for investors?
Browse our directory of 750+ angel investor groups, VCs, and accelerators across the United States.
About the Author
Jeff Barnes, MBA